Ligand Pharmaceuticals Incorporated LGND · Stock Open Ligand Pharmaceuticals Incorporated in new tab
Ligand Pharmaceuticals Incorporated Analysis (LGND)
Is Ligand Pharmaceuticals Incorporated a good investment? Ligand Pharmaceuticals Incorporated (LGND) is currently trading at 292.04 USD. Market analysts have a consensus price target of 323.30 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 37.44. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Ligand Pharmaceuticals Incorporated is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 11.83.
Investor FAQ
Does Ligand Pharmaceuticals Incorporated pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of 7.68.
Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
| Year | Total Dividends |
|---|---|
| ▸2010 |
0.12 USD
|
| July 2, 2010 | 0.1218 |
| ▸2007 |
11.86 USD
|
| April 19, 2007 | 9.3575 |
| April 19, 2007 | 2.5000 |
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 19, 2010 | 0.166667 |
| Nov. 2, 2022 | 1.603000 |
Community Discussion